Denali | Home
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative and lysosomal storage diseases through rigorous therapeutic discovery and development.
Denali
We would like to show you a description here but the site won’t allow us.
Denali | Patient Community Engagement - Engage Parkinsons
Denali is committed to collaborating with the patient community as we aim to defeat degeneration. Our focus is on the individuals and families we are working to support. By actively engaging the patient community and drawing insights from real-life experiences, we shape and guide our drug discovery and development process to bring new ...
Denali | Defeat Degeneration
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Denali | Parkinson's Disease Clinical Program
Denali, in partnership with Biogen, is evaluating DNL151, also known as BIIB122, an investigational medication in pill form that may delay the progression of Parkinsons's disease in people who are in the early stage of their condition. DNL151 is proposed to work by reducing the activity of LRRK2 proteins, which in turn may improve the function ...
today’s news •Interim results demonstrate average reduction of 64% (p < 0.001) from baseline in serum NfLafter 2 years of dosing with DNL310 in Phase 1/2 study
Denali | Frontotemporal Dementia (FTD) Clinical Program
Learn about Denali's Frontotemporal dementia (FTD) program. Frontotemporal dementia (FTD) associated with a mutation in the GRN (granulin) gene, referred to as FTD-GRN, is primarily caused by genetic factors.
Denali | Alzheimer's Disease Clinical Program
Denali is committed to working towards the discovery of potential treatments for Alzheimer’s disease, a progressive neurodegenerative disorder. Currently Denali’s pipeline has several possible future treatments that are targeting various potential causes of Alzheimer’s disease.
Leadership - Denali
Success is accelerated by experience, collaboration and leadership. Denali’s Board of Directors combines expertise across industry, academia, drug development and the investment community, unified by the mission to improve the lives of patients.
Denali has reported a greater than 90% mean reduction in CSF heparan sulfate at week 24 of treatment, remaining unchanged at week 104. Directly correlating the biomarker with clinical benefit is especially difficult in neuronal MPS patients who are not treated until they show obvious symptoms, Kakkis added.